These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35965582)

  • 1. Editorial: Metabolism of anti-cancer drugs: Interplay involving pharmacology and pharmacokinetics.
    Bapiro TE; Hayeshi R; Dandara C
    Front Oncol; 2022; 12():972718. PubMed ID: 35965582
    [No Abstract]   [Full Text] [Related]  

  • 2. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics.
    Smith DA; Jones BC; Walker DK
    Med Res Rev; 1996 May; 16(3):243-66. PubMed ID: 8727426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.
    De Paepe P; Belpaire FM; Buylaert WA
    Clin Pharmacokinet; 2002; 41(14):1135-51. PubMed ID: 12405864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Holy Grail of clinical pharmacology: prediction of drug pharmacokinetics and pharmacodynamics in the individual patient.
    Benet LZ
    Clin Pharmacol Ther; 2009 Aug; 86(2):133-4. PubMed ID: 19621007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
    Mathijssen RH; van Schaik RH
    Eur J Cancer; 2006 Jan; 42(2):141-8. PubMed ID: 16325399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender differences in human pharmacokinetics and pharmacodynamics.
    Fletcher CV; Acosta EP; Strykowski JM
    J Adolesc Health; 1994 Dec; 15(8):619-29. PubMed ID: 7696281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs.
    Kashuba AD; Nafziger AN
    Clin Pharmacokinet; 1998 Mar; 34(3):203-18. PubMed ID: 9533982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments.
    Gougis P; Hilmi M; Geraud A; Mir O; Funck-Brentano C
    Crit Rev Oncol Hematol; 2021 Oct; 166():103342. PubMed ID: 33930533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: Emerging talents in Frontiers in Pharmacology: Drug metabolism and transport 2022.
    Hinds TD; Valoti M; Lai Y; Dorlo TPC; Li Y
    Front Pharmacol; 2022; 13():1083163. PubMed ID: 36569302
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment.
    Gong Y; Haque S; Chowdhury P; Cory TJ; Kodidela S; Yallapu MM; Norwood JM; Kumar S
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):417-427. PubMed ID: 30951643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.
    Kivistö KT; Kroemer HK; Eichelbaum M
    Br J Clin Pharmacol; 1995 Dec; 40(6):523-30. PubMed ID: 8703657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics.
    Berthier J; Arnion H; Saint-Marcoux F; Picard N
    Life Sci; 2019 Aug; 231():116540. PubMed ID: 31176778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and challenges of cytokine pharmacology.
    Zídek Z; Anzenbacher P; Kmonícková E
    Br J Pharmacol; 2009 Jun; 157(3):342-61. PubMed ID: 19371342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric mice with humanized liver.
    Katoh M; Tateno C; Yoshizato K; Yokoi T
    Toxicology; 2008 Apr; 246(1):9-17. PubMed ID: 18248870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interaction studies of therapeutic proteins or monoclonal antibodies.
    Mahmood I; Green MD
    J Clin Pharmacol; 2007 Dec; 47(12):1540-54. PubMed ID: 17962422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of liver disease on pharmacokinetics. An update.
    Rodighiero V
    Clin Pharmacokinet; 1999 Nov; 37(5):399-431. PubMed ID: 10589374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
    Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
    Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.
    Chen ML
    Clin Pharmacokinet; 2006; 45(10):957-64. PubMed ID: 16984210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.
    Dostalek M; Akhlaghi F; Puzanovova M
    Clin Pharmacokinet; 2012 Aug; 51(8):481-99. PubMed ID: 22668340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug metabolism and ageing.
    Wynne H
    J Br Menopause Soc; 2005 Jun; 11(2):51-6. PubMed ID: 15970015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.